The Pulmonary Inflammation drugs in development market research report provides comprehensive information on the therapeutics under development for Pulmonary Inflammation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pulmonary Inflammation. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pulmonary Inflammation and features dormant and discontinued products.
GlobalData tracks 21 drugs in development for Pulmonary Inflammation by 19 companies/universities/institutes. The top development phase for Pulmonary Inflammation is preclinical with 16 drugs in that stage. The Pulmonary Inflammation pipeline has 16 drugs in development by companies and five by universities/ institutes. Some of the companies in the Pulmonary Inflammation pipeline products market are: BioCurity Pharmaceuticals, Pasteur Institute and ILiAD Biotechnologies.
The key targets in the Pulmonary Inflammation pipeline products market include Sphingolipid Delta(4) Desaturase DES1, Sphingosine Kinase 2, and Neuromedin B Receptor.
The key mechanisms of action in the Pulmonary Inflammation pipeline product include Ceramide Glucosyltransferase Inhibitor with one drug in Preclinical. The Pulmonary Inflammation pipeline products include six routes of administration with the top ROA being Inhalational and eight key molecule types in the Pulmonary Inflammation pipeline products market including Small Molecule, and Monoclonal Antibody.
Pulmonary Inflammation overview
Pulmonary Inflammation also called Pnemonia is an infection that inflames air sacs in one or both lungs, which may fill with fluid. Lung inflammation is favored by the combined action of oxidative stress, ACPA and Th17 cells. Widespread of pulmonary inflammation causes increased permeability of the alveolar capillary membrane leading to flooding and collapse of alveoli and severely impaired gas exchange. Pulmonary inflammation varies according to the type of initiating agent and the route of entry, distribution, and persistence.
For a complete picture of Pulmonary Inflammation’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
